GERN - Geron Corporation
| Previous Close | 1.4600 |
| Open | 1.4800 |
| Bid | 1.4700 x 4000 |
| Ask | 1.4800 x 2200 |
| Day's Range | 1.4500 - 1.5000 |
| 52 Week Range | 0.9500 - 6.9900 |
| Volume | 400,031 |
| Avg. Volume | 2,133,151 |
| Market Cap | 276.044M |
| Beta (3Y Monthly) | 2.66 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1630 |
| Earnings Date | May 4, 2017 - May 8, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.42 |
- Simply Wall St.•2 days ago
Such Is Life: How Geron (NASDAQ:GERN) Shareholders Saw Their Shares Drop 58%
Investing in stocks comes with the risk that the share price will fall. And there's no doubt that Geron Corporation...
- GlobeNewswire•6 days ago
Geron Appoints Vice President, Human Resources
Geron Corporation (GERN) today announced the appointment of Shannon Odam as Vice President, Human Resources. Ms. Odam joins other recently recruited senior leadership to further strengthen the organization as it expands its operations to support the planned opening of the Phase 3 portion of IMerge in lower risk myelodysplastic syndromes for screening and enrollment in the summer of 2019. As Vice President, Human Resources, Ms. Odam will lead all aspects of a comprehensive human resources function, including oversight of policies and operations for leadership and talent management, training, organizational development, operational effectiveness and workforce planning.
- GlobeNewswire•9 days ago
Geron Reports Two Imetelstat Data Presentations at European Hematology Association Annual Congress
Updated 8-week RBC-TI rate for the Phase 2 portion of IMerge increased to 42%, from 37% in December 2018Updated 24-week RBC-TI rate for the Phase 2 portion of IMerge increased.
- GlobeNewswire•16 days ago
Geron to Webcast KOL Event on June 25, 2019
Geron Corporation (GERN) today announced that the Company will webcast an event on June 25, 2019, featuring key opinion leaders (KOLs) who are authors of imetelstat data presentations being made at the 24th Annual Congress of the European Hematology Association (EHA). The KOLs will reprise the presentations made at EHA, and Geron’s management team will provide an update regarding progress towards the Company’s 2019 objectives, including the opening of the planned Phase 3 portion of IMerge for screening and enrollment in the summer of 2019. Uwe Platzbecker, M.D., Director, Medical Department I – Hematology and Cell Therapy, University of Leipzig Medical Center, Leipzig, Germany, will review efficacy and safety data presented at EHA from the Phase 2 portion of IMerge, the ongoing Phase 2/3 clinical trial of imetelstat in patients with lower risk myelodysplastic syndromes.
- Benzinga•18 days ago
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
Biotech stocks staged a steady recovery last week. ASCO presentations dominated the headlines, with Iovance Biotherapeutics Inc (NASDAQ: IOVA ) and Mirati Therapeutics Inc (NASDAQ: MRTX ) among the biggest ...
- Zacks•25 days ago
Why Is Geron (GERN) Down 22% Since Last Earnings Report?
Geron (GERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks•29 days ago
Geron Stock Up More Than 50% in 2019 So Far: Here's Why
Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.
- Motley Fool•last month
Did Geron's Big Announcement Just Go Unnoticed?
Geron hints at a way forward for imetelstat in myelofibrosis, but the market isn't buying it.
- GlobeNewswire•last month
Geron Announces Two Presentations on Imetelstat at Upcoming European Hematology Association Annual Congress
Geron Corporation (GERN) today announced that two abstracts containing clinical data and analyses related to imetelstat, the Company’s first-in-class telomerase inhibitor, have been accepted for presentation at the 24th European Hematology Association (EHA) Annual Congress to be held in Amsterdam, the Netherlands, from June 13-16, 2019. “We appreciate the opportunity to present additional data and analyses at EHA from the ongoing imetelstat clinical trials,” said John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer.
- GlobeNewswire•last month
Geron Provides Imetelstat Program Update
Geron Corporation (GERN) today provided an update to its 2019 corporate objectives for the imetelstat program. “2019 is off to a good start with the imetelstat IND transfer now complete, enabling us to move forward with the planned opening of the Phase 3 clinical trial in lower risk myelodysplastic syndromes for screening and enrollment, which we continue to expect by mid-year 2019,” said John A. Scarlett, M.D., Chairman and Chief Executive Officer. “Our new development team has refined our regulatory strategies for myelofibrosis, which we plan to discuss at an End of Phase 2 meeting with the FDA by the end of the first quarter of 2020.
- GlobeNewswire•last month
Geron Continues to Build Senior Leadership of Its Development Team
Geron Corporation (GERN) today announced that it is continuing to build the senior leadership of its development team with the addition of a Vice President, Biometrics, and a Vice President, Manufacturing.
- Zacks•2 months ago
Geron's (GERN) Q1 Earnings Beat, Revenues Miss, Stock Up
Geron (GERN) posts narrower-than-expected loss in first-quarter 2019 but misses on revenues. Operating expenses increase on a year-over-year basis.
- Associated Press•2 months ago
Geron: 1Q Earnings Snapshot
The Menlo Park, California-based company said it had a loss of 5 cents per share. The drugmaker posted revenue of $57,000 in the period. The company's shares closed at $1.82. A year ago, they were trading ...
- GlobeNewswire•2 months ago
Geron Corporation Reports First Quarter 2019 Financial Results
MENLO PARK, Calif., May 02, 2019 -- Geron Corporation (Nasdaq: GERN) today reported financial results for the first quarter ended March 31, 2019. As of the quarter-end, the.
- Zacks•2 months ago
Analysts Estimate Geron (GERN) to Report a Decline in Earnings: What to Look Out for
Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.•2 months ago
Can We See Significant Institutional Ownership On The Geron Corporation (NASDAQ:GERN) Share Register?
A look at the shareholders of Geron Corporation (NASDAQ:GERN) can tell us which group is most powerful. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies...
- Motley Fool•2 months ago
3 Cancer Treatment Stocks to Buy in April
These three cancer stocks have tremendous upside potential.
- GlobeNewswire•2 months ago
Geron Expands Senior Leadership of Its Development Team
MENLO PARK, Calif., April 18, 2019 -- Geron Corporation (Nasdaq: GERN) today announced an expansion of its development team’s senior leadership with the addition of three.
- Benzinga•3 months ago
Geron's Blood Cancer Candidate Creates Buying Opportunity, Needham Says In Upgrade
Geron Corporation (NASDAQ: GERN ) announced in September that Johnson & Johnson (NYSE: JNJ )'s Janssen unit opted to terminate a collaboration and licensing agreement between the companies for imetelstat, ...
- Reuters•3 months ago
BRIEF-China's Geron Says Controlling Shareholder Plans To Unload Up To 6 Pct Stake In The Company
April 8 (Reuters) - Geron Co Ltd: * SAYS CONTROLLING SHAREHOLDER PLANS TO UNLOAD UP TO 6 PERCENT STAKE IN THE COMPANY WITHIN SIX MONTHS Source text in Chinese: https://bit.ly/2IiMtRX Further company coverage: ...
- Zacks•3 months ago
Why Is Geron (GERN) Up 27.3% Since Last Earnings Report?
Geron (GERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GlobeNewswire•3 months ago
Geron to Present at Needham Healthcare Conference
MENLO PARK, Calif., April 02, 2019 -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to.
- GlobeNewswire•3 months ago
Geron Appoints Two New Independent Board Members
MENLO PARK, Calif., March 28, 2019 -- Geron Corporation (Nasdaq: GERN) today announced the appointments of Dawn C. Bir and Elizabeth G. O’Farrell as independent members of its.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of GERN earnings conference call or presentation 7-Mar-19 9:30pm GMT
Q4 2018 Geron Corp Earnings Call
- GlobeNewswire•3 months ago
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 78,400 shares of Geron common stock as inducements to two newly-hired employees in connection with commencement of employment with the Company. The stock options were granted on March 20, 2019 at an exercise price of $1.77 per share, which is equal to the closing price of Geron common stock on the date of grant. Each stock option granted has a 10-year term and vests over four years, with 12.5% of the shares underlying the option vesting on the six-month anniversary of commencement of employment and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates.
